Risperidona en el tratamiento de la esquizofrenia crónica: Estudio multicéntrico comparativo versus haloperidol

Actas Espanolas de Psiquiatria

Volumn 24, Issue 4, 1996, Pages 165-172

  Lopez Ibor, J J ^b   Ayuso, J L ^b   Gutierrez, M ^c   Guimon, J ^d   Herraiz, M L ^e,f   Chinchilla, A ^a   Ayuso Jr , J L ^b   Gonzalez Pinto, A ^c   Eguiluz, I ^d   Fernandez, A ^e  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c HOSPITAL TXAGORRITXU   (Spain)

^d HOSPITAL DE BASURTO   (Spain)

^e Dpto Investigacion Clinica   (Spain)

^f Janssen Research Foundation   (Spain)

Author keywords

Haloperidol; Risperidone; Schizophrenia; Tolerability

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERANCE; EXTRAPYRAMIDAL SYSTEM; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SINGLE BLIND PROCEDURE;

ADULT; ANTIPSYCHOTIC AGENTS; DRUG TOLERANCE; EXTRAPYRAMIDAL TRACTS; FEMALE; HALOPERIDOL; HUMANS; MALE; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SINGLE-BLIND METHOD;

EID: 3142554633     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. CREESE, I.; BURT, D. R. y SNYDER, S. H.: «Dopamine receptor binding predicts clinical and pharmacological potencies of antishizophrenic drugs». Science 192: 481-483, 1976.
2. CASEY, D. E.: «Neuroleptic drug-induced extrapyramidal syndromes and tardibe dyskinesia». Schizophren Res. 4: 109-120, 1991.
3. VAN PUTTEN, T.: «Why do schizophrenic patients refuse to take their drugs»? Arch. Gen. Psychiatr. 31: 67-72, 1974.
4. CROW, T. J.: «The two-syndrome concept: Origins and status». Schizophr Bull. 11: 471-486, 1985.
5. KANE, J. M. y MAYERHOFF, D.: «Do negative symptoms respond to pharmacological treatment»? Br. J. Psychiatr. 155 (7): 115-118, 1989.
6. KEEFE, R. S. E.; MOHS, R. C.; LOSONCZY, M. F.; DAVIDSON, M.; SILVERMAN, J. M.; KENDLER, K. S.; HORVATH, T. B., NORA R. y DAVIS K.L. «Characteristics of very poor outcome schizophrenia». Am. J. Psychiatr. 144: 889-895, 1987.
7. McCREADIE, R. G.; STEWART, M.; ROBERTSON, L. y DINGWALL, J. M.: «The Stottish survey of old longstay impatients». Br. J. Psychiatr. 158: 398-402, 1991.
8. BLEICH, A.; BROWN, S. I., KAHN, R. y VAN PRAAG, H.: «The role of serotonin in shizophrenia». Schizophr Bull 14: 297-315, 1988.»
9. MELTZER, H. Y.: «Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia». Psychopharmacol 99: S18-S27, 1989.
10. 2 antagonistic properties». J. Pharmacol. Exp. Ther. 244: 685-693, 1988.
11. LEYSEN, J. E.; GOMMEREN, W.; EENS, A.; DE CHAFFOY DE COURCELLS, D.; STOOF, J. C. y JANSSEN, P. A. J.: «The biochemical profile of risperidone, a new antipsychotic». J. Pharmacol. Exp. Ther, 246: 661-670, 1988.
12. MEGENS, A. A. H. P.; AWOUTERS, F. H. L. y NIEMEGEERS, C. J. E.: «Differential effects of the new antipsychotic risperidone on large and small motor movements in rats: A comparison with haloperidol». Psychopharmacol 95: 493-496, 1988.
13. 2 antogonism in schizophrenia: clinical, extrapyramidal and neurodendocrine response in a preliminary study with risperidone (R 64 766)». Hum. Psychopharmacol, 5: 225-231, 1990.
14. 2 antagonist risperidone (R 64 766) in the treatment of chronic psychosis: an open dose-finding study». Schizophr Bull 2: 411-415, 1989.
15. CHOUINARD, G.; JONES, B. y REMINGTON, G. et al.: «A canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients». Journal of Clinical Psychopharmacology 13: 25-40, 1993.
16. CLAUS, A.; BOLLEN, J.; DE CUYPER, H.; ENEMAN, M; MALFROID, M.; PEUSKENS, J. y HEYLEN, S.: «Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: A multicenter double-blind comparative study». Acta Psychiatr Scand 85: 295-305, 1992.
17. GELDERS, Y. G.; HEYLEN, S. L. E.; VANDEN BUSSCHE, G.; REYNTJENS, A. J. M. y JANSSEN, P. A. J.: «Pilot clinical investigation of risperidone in the treatment of psychotic patients». Pharmacopsychiatry 23: 206-211, 1990.
18. MARDER, S. R. y MEIBACH, R. C.: «Risperidone in the treatment of schizophrenia». Am. J. Psychiatry, 151, 825-835, 1994.
19. MECO, G.; BEDINI, L.; BONIFATI, V. y SONSONI, U.: «Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia: A single-blind crossover study versus placebo». Curr. Ther Res 46: 876-883, 1989.
20. MESOTTEN, F.; SUY, E.; PIETQUIN, M.; BURTON, P.; HEYLEN, S. y GELDERS, Y.: «Therapeutic effect and safety of increasing doses of risperidone (R 64 766) in psychotic patients». Psychopharmacol 99: 445-449, 1989.
21. AMERICAN PSYCHIATRIC ASSOCIATION. «Diagnostic and statistical manual of mental disorders (DSM-III-R)». Washington DC, 1987.
22. KAY, S. R.; FISZBEIN, A. y OPLER, L. A.: «The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia». Schizophrenia Bulletin, 13: 261-276, 1987.
23. KAY, S. R.; OPLER, L. A. y LINDENMAYER, J. P.: «Reliability and validaty of the Positive and Negative Syndrome Scale for Schizophrenics». Psychiatr. Res 23: 99-110, 1988.
24. GUY, W.: ECDEU Assessment Manual for Psychopharmacology (revised). Published by DHEW, No. (ADM) 73-388, Rockville, MD: National Institutes of Mental Health, 1976.
25. OVERALL, J. F. y GORHAM, D. R.: «The Brief Psychiatric Rating Scale». Psycholog. Rep. 10: 799-812, 1962.
26. CHOUINARD, G.; ANNABLE, L.; ROSS-CHOUINARD, A. et al: «Ethopropazine and benztropine in neuroleptic-induced parkinsonism». Journal of Clinical Psychiatry 40: 147-152, 1979.
27. CHOUINARD, G.; ROSS-CHOUINARD, A.; ANNABLE, L. y JONES, B. D.: «The Extrapyramidal Symptom Rating Scale». Can J. Neurol Sci 7: 233, 1980.
28. LINGJAERDE, O.; AHLFORS, U. G.; BECH, P.; DECKER, S. J. y ELGEN, K.: «The UKU side effect rating scale». Acta Psychiatr. Scand. 76 (334): 81-94, 1987.
29. LEE, E. T.: «Stastistical Methods for Survival Data Analysis». Lifetime Learning Publications, Belmont, Canada, 1980.
30. LEHMANN, E. L.: «Nonparametrics, Statistical Methods Bases on Ranks». Holden-Day, San Francisco, 1975.
31. GELDERS, Y. G.: «Thymosthenic agents, a novel approach in the treatment of schizophrenia». Br. J. Psychiatr. 155 (5): 33-36, 1989.
32. BARNES, T. R. E.: «The present status of tardive dyskinesia and akathisia in the treatment of schizophrenia». Psychiatr. Dev. 4: 301-319, 1987.
33. CHOUINARD, G.; ANNABLE, L.; ROSS-CHOUNARD, A. y MERCIER, P.: «A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases». J. Clin. Psychopharmacol. 8: 21S-26S, 1988.
34. PEUSKENS, J. «On behalf of The Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, pararellgroup study versus haloperidol». Br. J. Psychiatry, 166, 712-726, 1995.